FDA Approves Conditional Pathway for Cannabinoid Drug to Treat Canine Bone Cancer Pain

The FDA has cleared a pathway for an investigational oral solution of cannabidiol (CBD) and tetrahydrocannabinol (THC) aimed at managing bone cancer pain in dogs to pursue conditional approval. This decision, announced on October 5, 2026, recognizes CannEpil, developed by Endovia Health Sciences and Lupvindol BioSciences, under the agency’s Minor Use and Minor Species (MUMS) program as a qualifying “minor use.”

CannEpil remains classified as an investigational new animal drug and has not yet received FDA approval. The conditional approval will allow the companies to market the drug while they collect additional data to demonstrate its effectiveness, which differs from the substantial evidence required for full approval. The product must meet safety and manufacturing standards, and the conditional approval lasts for one year, with the possibility of annual renewal for up to four additional years.

Endovia Health Sciences and Lupvindol BioSciences are scheduled to meet with the FDA on November 19, 2026, to discuss regulatory submissions, manufacturing requirements, and necessary studies for seeking conditional approval. In addition to regulatory efforts, the companies are establishing US-based manufacturing capabilities for CannEpil, anticipating a potential veterinary launch in 2027, contingent on FDA review and manufacturing readiness.

Brady Cobb, interim CEO of Endovia Health Sciences, expressed that this determination marks a significant regulatory milestone for CannEpil and emphasized the company's proactive approach toward commercialization. He noted that the veterinary program aims to meet an unmet clinical need for dogs experiencing pain due to cancer.

This initiative is part of a wider effort to develop cannabinoid-based therapeutics that could have future applications in both veterinary and human medicine.